Lipid nanoparticles (LNPs) have emerged as the leading non-viral delivery platform for nucleic acid therapeutics, protein antigens, and other delicate cargoes. Their commercial success, however, depends on far more than the composition of the four lipid components. The route of administration determines where the LNP travels, which cells it encounters, how it is internalized, and ultimately whether the cargo reaches the cytosol in a functional form. The same formulation administered in vivo by different routes can produce drastically different biodistribution, immunogenicity, and therapeutic outcomes, making route selection one of the most consequential decisions in any LNP program.
This resource maps the common LNP delivery pathways by route of administration, examining the formulation design considerations, biological delivery mechanisms, and appropriate application scenarios for each. The discussion is organized around six major routes (intravenous, intramuscular and subcutaneous, intradermal and microneedle, oral, inhaled and intranasal, and local and topical) and concludes with a practical framework for route selection. By the end, formulation scientists, project leaders, and CRO partners should be able to identify the most suitable delivery route for a given payload, target tissue, and research objective, and understand the formulation adjustments required to make that route work.
Intravenous (IV) injection provides direct access to the systemic circulation and is one of the most established routes for LNP-mediated delivery. Because there is no absorption step before particles enter the bloodstream, IV delivery is particularly useful when the target is accessible from the vascular compartment, including hepatocytes, splenic immune cells, circulating cells, vascular endothelium, and selected extrahepatic tissues. However, direct blood exposure also means that the LNP immediately encounters plasma proteins, filtration organs, phagocytic cells, and biological clearance mechanisms.
The key development question is therefore not simply whether an LNP remains intact in buffer, but whether its physicochemical properties support the desired biological identity after contact with blood.
IV LNPs usually employ a four-component architecture consisting of an ionizable lipid, helper phospholipid, cholesterol, and PEG-lipid. The optimal composition is target- and payload-dependent, but several quantitative parameters provide useful starting points for formulation screening.
Ionizable lipid apparent pKa:For hepatic RNA delivery, an apparent pKa around 6.2-6.5 is frequently reported as a productive design region. At physiological pH near 7.4, ionizable lipid nanoparticles remain largely neutral, reducing strong nonspecific electrostatic interactions. As the endosomal environment acidifies, protonation increases and promotes interaction with anionic endosomal membrane lipids. This 6.2-6.5 range should be treated as a hepatic RNA benchmark rather than a universal optimum because extrahepatic targeting and non-IV routes may favor different ionization behavior.
PEG-lipid content:Approximately 1-2 mol% PEG-lipid is a common starting region in conventional RNA-LNP formulations. PEG reduces aggregation and controls particle size, but excessive surface shielding can suppress cellular interactions. PEG anchor chemistry is equally important because short lipid anchors can desorb more rapidly than long hydrophobic anchors. LNP PEG-lipid optimization should therefore consider PEG percentage, molecular weight, lipid anchor, and shedding kinetics together.
Particle size and dispersity:Many systemic RNA-LNP formulations are engineered within approximately 60-100 nm hydrodynamic diameter. A PDI below 0.2 is generally desirable for a relatively narrow particle population, while values approaching or below 0.15 provide tighter control for comparative formulation studies. These values are practical development targets rather than fixed acceptance limits.
Ionizable lipid-to-RNA ratio:The N/P ratio influences nucleic acid association, encapsulation efficiency, surface charge, and intracellular release. Ratios around 4-6 are frequently used as an initial screening region for selected RNA systems, but the useful range changes substantially with lipid headgroup chemistry, RNA size, buffer pH, and mixing conditions. LNP encapsulation efficiency optimization is therefore preferable to applying a fixed N/P ratio across different payloads.
Table 1. Practical Starting Windows for IV RNA-LNP Development.
| Parameter | Common Starting Region | Main Function | Important Qualification |
| Apparent pKa | Approximately 6.2-6.5 | Circulation neutrality and endosomal ionization | Best supported for hepatic RNA delivery; not universal |
| PEG-lipid | Approximately 1-2 mol% | Size control and colloidal stabilization | Anchor chemistry and shedding rate also matter |
| Hydrodynamic diameter | Approximately 60-100 nm | Vascular transport and tissue access | Target organ may require a different size region |
| PDI | <0.20 as a useful development target | Particle population consistency | Interpret together with size distribution profile |
| N/P ratio | Often screened around 4-6 | RNA association and encapsulation | Strongly dependent on lipid and payload chemistry |
Immediately after IV administration, plasma proteins adsorb onto the LNP surface and create a dynamic protein corona. This corona can strongly influence where the particle travels and which receptors recognize it. A well-characterized example is ApoE adsorption followed by LDL receptor-mediated uptake in hepatocytes, which contributes to the natural liver tropism of many conventional ionizable LNPs. As a result, successful IV delivery to extrahepatic tissues often requires intentional control of lipid composition, surface chemistry, size, or targeting ligands rather than simply increasing the injected dose.
After tissue access, productive delivery still requires cellular internalization, intracellular trafficking, and cytosolic payload release. Tissue accumulation alone is therefore not a sufficient indicator of performance. Combining nanoparticle in vivo distribution analysis with cell-level uptake and functional payload measurements helps distinguish an organ-targeting problem from an intracellular delivery problem.
Hepatic gene silencing:The natural ApoE-LDLR interaction makes systemic LNP delivery particularly relevant for hepatocyte-directed RNA research. Lipid nanoparticles for siRNA delivery can exploit this biological pathway while formulation optimization controls potency and off-target distribution.
Systemic mRNA expression:Lipid nanoparticles for mRNA delivery can support transient protein expression when the intended cells are reachable from circulation.
Gene editing payloads:Systemic administration is also studied for delivery of genome-editing components. Lipid nanoparticles for CRISPR RNP delivery require coordinated optimization of payload loading, particle stability, tissue distribution, uptake, and cytosolic release.
Liver-selective programs:Where hepatic localization is desired, liver-targeted LNP development can refine rather than eliminate the endogenous liver-targeting mechanism.
Intramuscular (IM) and subcutaneous (SC) administration place LNPs into an interstitial tissue compartment rather than directly into the bloodstream. This creates a fundamentally different delivery pathway consisting of injection-site dispersion, interaction with extracellular matrix, uptake by local cells, and transport toward draining lymphatics. IM and SC routes are therefore particularly relevant when local expression and lymphoid-organ access are more important than immediate systemic exposure.
Particle size for lymphatic access:Nanoparticles approximately 20-100 nm are widely reported to have favorable access to afferent lymphatics after interstitial administration. Very small particles may leave the injection site rapidly and can enter blood capillaries, whereas particles above approximately 100 nm increasingly experience interstitial retention and may depend more strongly on uptake by migratory cells.
Surface charge:The extracellular matrix contains negatively charged glycosaminoglycans and proteoglycans. Strongly cationic particles can therefore become electrostatically retained at the injection site. Near-neutral or mildly negative surface characteristics often support better interstitial mobility, although excessive reduction in cell interaction can decrease uptake by antigen-presenting cells.
Ionizable lipid behavior:Route-specific lipid optimization is important. Whereas apparent pKa values around 6.2-6.5 are frequently associated with hepatic IV RNA delivery, some IM mRNA studies have identified slightly higher apparent pKa values, approximately 6.6-6.9, as useful formulation benchmarks. This illustrates why an IV-optimized LNP should not automatically be assumed to be optimal after IM administration.
Antigen and adjuvant coordination:Lipid nanoparticles for co-delivery can place antigen-encoding cargo and an immune-modulating payload within the same particle population, increasing the probability that both reach the same antigen-presenting cells.
Two mechanisms can operate in parallel. First, sufficiently mobile LNPs can move through the interstitial space and enter afferent lymphatic capillaries, eventually reaching draining lymph nodes. Second, LNPs can be internalized by dendritic cells, macrophages, or other local cells; migratory immune cells may subsequently carry associated material toward lymph nodes. The relative contribution of direct drainage and cell-mediated transport varies with particle size, formulation, tissue environment, and time after administration. For this reason, lymph node-targeted LNP development should evaluate both particle-level distribution and cell-type association rather than relying on total lymph-node signal alone.
mRNA antigen delivery:Lipid nanoparticle vaccine development commonly uses IM or SC administration when local expression and lymphatic immune-cell access are desired.
Self-amplifying RNA:Lipid nanoparticles for saRNA delivery must accommodate larger RNA molecules while maintaining particle size, RNA integrity, and productive intracellular release.
Protein and peptide antigens:LNP-based protein delivery and LNP-based peptide delivery can be designed around antigen protection, release kinetics, and uptake by antigen-presenting cells.
BOC Sciences can compare IV, IM, and SC formulation requirements and identify how particle size, lipid composition, surface properties, and payload design affect tissue distribution and functional delivery.
Intradermal injection and microneedle-assisted administration exploit the high density of antigen-presenting cells and lymphatic vessels within the skin. Microneedles additionally bypass the stratum corneum, which is the dominant barrier to passive topical transport of intact LNPs. For LNP research, however, a microneedle system is not simply an alternative injection device. Particle formulation, drying conditions, polymer matrix, needle geometry, release kinetics, and deposition depth all influence the final delivery outcome.
Concentrated formulation design:Intradermal and microneedle administration generally operate with smaller administration volumes than conventional IM injection. High LNP concentration can therefore become necessary, increasing the risk of particle-particle interactions, viscosity changes, aggregation, or RNA instability.
Dissolving microneedles:LNPs can be embedded within water-soluble polymer matrices that dissolve after insertion into the skin. During fabrication, LNPs may experience dehydration, concentration gradients, interfacial stress, and polymer interactions. Lipid nanoparticle manufacturing for these systems should therefore include characterization before fabrication and after release from the microneedle matrix.
Dry-state stabilization:Disaccharides such as sucrose and trehalose are frequently investigated as cryoprotective or lyoprotective excipients for RNA-LNPs because they can reduce aggregation and structural damage during freezing or dehydration. The optimal concentration remains formulation-specific. LNP cryoprotectant screening can compare particle size, PDI, encapsulation, RNA integrity, and functional delivery after drying and rehydration.
Cell-selective surface design:Where enhanced dermal antigen-presenting cell interaction is required, surface ligands can be investigated. Mannose-conjugated lipid nanoparticles, for example, can be evaluated for lectin-receptor-mediated uptake rather than relying only on nonspecific skin-cell internalization.
Table 2. Microneedle Formats and LNP Development Requirements.
| Format | LNP State | Main Formulation Stress | Recommended Evaluation |
| Dissolving microneedle | Embedded in polymer matrix | Drying, concentration, matrix interaction | Release, size, PDI, EE%, RNA integrity |
| Coated microneedle | Concentrated surface layer | Coating uniformity and dehydration | Delivered dose and post-release activity |
| Dry powder system | Solid-state LNP formulation | Moisture and reconstitution stress | Solid-state stability and redispersibility |
| Hollow microneedle | Liquid dispersion | Flow resistance and depth control | Injectability and tissue distribution |
Microneedles bypass the outer skin barrier and place LNPs close to keratinocytes, Langerhans cells, dermal dendritic cells, macrophages, and lymphatic capillaries. Once released, LNPs may be taken up locally, drain through lymphatics, or be captured by antigen-presenting cells that later migrate toward draining lymph nodes. The exact pathway depends on deposition depth, particle mobility, and the rate at which the microneedle matrix dissolves or releases its cargo. Therefore, successful skin delivery requires coordination between needle geometry and LNP transport properties rather than formulation optimization alone.
Intradermal (ID) and microneedle delivery are best suited to dose-sparing vaccine strategies, needle-free immunization programs, and indications where patient compliance is a priority.
Dose-sparing pandemic vaccines: Intradermal delivery of mRNA LNPs can achieve comparable antibody titers at 1/5 to 1/10 of the IM dose, valuable for global vaccine access.
Microneedle patch vaccines: Dissolvable patches remove the need for cold-chain-trained administrators and enable self-administration, expanding access in low-resource settings.
Therapeutic cancer vaccines: Intradermal delivery of neoantigen-encoding LNPs enables direct engagement of dermal DCs for tumor-specific T cell priming.
Allergen-specific immunotherapy: Intradermal delivery of allergen-encoding LNPs offers a controlled approach to desensitization.
Oral LNP delivery offers direct access to the gastrointestinal tract but remains substantially more challenging than parenteral delivery for nucleic acid payloads. The formulation encounters a sequence of distinct environments rather than one barrier: gastric acid, digestive enzymes, intestinal bile salts, mucus, epithelial cells, and intracellular trafficking mechanisms. A successful oral formulation therefore requires both extracellular protection and productive cellular delivery.
Gastric pH protection:Stomach pH can fall to approximately 1-2.5, creating a highly acidic environment that can alter LNP ionization, colloidal stability, and payload integrity. Enteric matrices or pH-responsive outer dosage forms can be used to delay LNP exposure until the formulation reaches a more favorable intestinal environment.
Bile and enzyme resistance:Bile salts can insert into lipid assemblies and promote lipid extraction or particle reorganization, while lipases and other digestive enzymes create additional degradation pathways. Oral LNP development should therefore measure particle size, PDI, payload retention, and functional activity after exposure to biorelevant gastric and intestinal media rather than assessing buffer stability alone.
Lipid composition:Increasing membrane rigidity, adjusting cholesterol, or introducing additional lipid species can improve resistance to GI destabilization in selected systems. For example, one recent oral RNA-LNP study held total cationic plus ionizable lipid at 50 mol% and identified a formulation containing 20 mol% cationic lipid and 30 mol% ionizable lipid that showed improved resistance to bile-salt exposure. This composition is a formulation-specific research example, not a general recommendation. Lipid nanoparticle formulation should screen such ratios experimentally.
Mucus interaction:Oral formulations can follow two different strategies. Mucoadhesive systems intentionally extend intestinal residence, whereas mucus-penetrating systems reduce strong adhesive interactions to improve access to the epithelium. Which strategy is preferable depends on the intended site of action and release kinetics.
Solid dosage integration:Freeze-dried or otherwise stabilized LNPs may be incorporated into capsules, tablets, or protective matrices. Lipid nanoparticle stability should then be evaluated after drying, storage, rehydration, and simulated GI exposure.
After release in the intestine, LNPs must first move through or interact productively with the mucus layer. Particles reaching the epithelium may be internalized by enterocytes or other epithelial cells, while particulate uptake by microfold (M) cells overlying Peyer's patches represents another possible transport route for selected formulations. M-cell transport should not be assumed to be the dominant pathway for every LNP; its contribution depends on particle properties and intestinal location. Lymphatic transport may occur after epithelial processing or uptake of lipid-associated material, but achieving reproducible systemic exposure requires additional optimization beyond local GI cell transfection.
Local intestinal RNA delivery:The most direct research objective is functional delivery to intestinal epithelial or immune cells without requiring intact particles to achieve high systemic exposure. Lipid nanoparticles for RNA delivery can be screened for local gene silencing or transient expression under route-relevant conditions.
Mucosal vaccine research:Oral LNP systems may be designed to interact with gut-associated lymphoid tissues and intestinal antigen-presenting cells.
Repeated local delivery:Oral administration may also be investigated where repeated exposure to a GI target is desired. However, systemic oral RNA delivery remains substantially more difficult because gastrointestinal survival, epithelial transport, lymphatic or vascular entry, and subsequent tissue targeting must all succeed sequentially.
BOC Sciences can evaluate LNP performance across pH, bile, enzyme, mucus, and intestinal-media conditions and help identify whether formulation instability or cellular delivery is limiting your oral LNP project.
Inhaled and intranasal routes place LNPs closer to respiratory or nasal target tissues than systemic administration. However, these routes introduce formulation variables that do not exist for conventional injections, including aerosol generation, aerodynamic deposition, mucus transport, mucociliary clearance, pulmonary surfactant interactions, and device-induced particle stress.
Liquid nebulization:LNP dispersions delivered by nebulization can experience shear, extensional stress, repeated air-liquid interface exposure, and concentration effects during aerosol formation. Particle size and encapsulation measured before nebulization therefore do not predict post-device performance. Size, PDI, payload leakage, RNA integrity, and functional expression should be compared before and after aerosolization.
Dry-powder formulation:Nanoscale LNPs are generally too small to possess optimal aerodynamic behavior by themselves. They can instead be incorporated into microscale dry-powder structures that disperse into the respiratory tract and subsequently release the nanoscale LNP after contact with airway fluid.
Aerodynamic diameter:An aerodynamic particle diameter of approximately 1-5 µm is widely used as a practical target for lower respiratory tract deposition. This value refers to the aerosolized droplet or dry carrier particle, not the original 50-100 nm-scale LNP. Aerosol particles above approximately 5 µm increasingly deposit in upper airways by inertial impaction, while very small aerosol particles may remain suspended and be exhaled.
Mucus-compatible surface design:Neutral or strongly shielded surfaces can reduce adhesive interactions with airway mucus, but excessive PEG density may reduce subsequent epithelial uptake. Respiratory LNP development therefore requires a balance between mucus transport and cellular interaction.
Target-site formulation:Lung-targeted LNP development should consider both nanoscale LNP properties and the macroscopic aerosol characteristics produced by the selected administration system.
Table 3. Respiratory LNP Size Parameters at Different Scales.
| Parameter | Relevant Scale | Primary Function | Interpretation |
| LNP hydrodynamic diameter | Tens to approximately 100 nm | Cell interaction and intracellular delivery | Measured after LNP release or redispersion |
| Aerosol aerodynamic diameter | Approximately 1-5 µm | Lower-airway deposition | Refers to inhaled droplet or carrier particle |
| MMAD | Device-dependent | Regional respiratory deposition | Depends on particle size, density, and shape |
| Post-aerosol PDI | LNP-scale measurement | Detects aggregation or structural disruption | Compare with pre-aerosol values |
Following deposition, LNPs must encounter a dynamic surface containing mucus, airway fluid, pulmonary surfactant, epithelial cells, and immune cells. Mucus can trap particles and transport them away through mucociliary clearance before productive uptake occurs. In the lung, surfactant and extracellular proteins can remodel the LNP surface and change cellular interactions. Productive delivery can involve uptake by airway epithelial cells, alveolar epithelial cells, macrophages, or other resident populations depending on deposition region and formulation. For intranasal delivery, local epithelial uptake and immune-cell interaction are common goals, while transport toward olfactory or trigeminal-associated regions is investigated for selected nose-to-brain strategies but should not be assumed for standard nasal LNPs.
Pulmonary RNA expression:Respiratory LNPs can be studied for local expression or gene silencing in airway and lung cells without relying on initial systemic distribution.
Oligonucleotide delivery:Lipid nanoparticles for ASO delivery can be investigated where local respiratory exposure provides an advantage over systemic delivery.
Mucosal vaccine research:Intranasal systems may provide direct access to nasal mucosa and associated immune structures.
Local lung targeting:Pulmonary administration is particularly valuable when high respiratory exposure is desired but systemic LNPs show dominant hepatic distribution.
BOC Sciences can compare LNP properties before and after aerosolization and optimize lipid composition, excipients, particle integrity, respiratory deposition, cellular uptake, and functional payload delivery.
Local delivery places LNPs directly at or near the intended tissue and reduces the transport distance required before cellular exposure. Depending on the target, administration may involve direct tissue injection, topical formulations, ocular delivery, mucosal application, or LNP incorporation into a local gel or depot. The formulation challenge shifts from systemic biodistribution to local retention, tissue penetration, and spatially uniform cell access.
Free LNP dispersions:Low-viscosity liquid systems can provide rapid distribution from the administration point but may also leave the target tissue quickly. Buffer composition, osmolality, LNP concentration, and colloidal stability must therefore be matched to the local environment.
LNP-hydrogel systems:Hydrogels can create a local depot that slows dispersion and extends particle residence. The matrix must release structurally intact LNPs rather than trapping them permanently or inducing fusion and aggregation. Release kinetics should be measured together with LNP size and payload retention.
Particle size and mobility:Smaller LNPs generally experience less steric restriction within extracellular matrices, while larger or more adhesive particles tend to remain closer to the administration site. There is no universal optimal diameter because matrix pore size, collagen density, charge, and interstitial pressure differ among tissues.
Surface engineering:Modifying charge, PEG architecture, or surface ligands can alter local retention and tissue penetration. Nanoparticle functionalization services can be used where passive diffusion alone does not provide sufficient cell or tissue selectivity.
Ocular formulation:Eye delivery is particularly route-specific. Topical formulations encounter tear turnover and corneal barriers, while intraocular routes encounter vitreous diffusion and retinal tissue barriers. Ocular LNP delivery development therefore requires separate optimization rather than application of a generic local-delivery formulation.
Once placed locally, LNPs distribute through diffusion, convection, matrix interactions, cellular uptake, and local clearance. Direct proximity to target tissue does not eliminate intracellular barriers. LNPs still need to bind or contact relevant cells, enter through endocytic pathways, avoid nonproductive lysosomal trafficking, and release payload into the correct intracellular compartment. In dense tissues, spatial distribution can become the limiting step: cells close to the administration site may receive high particle exposure while deeper regions remain poorly reached. Measuring both local particle distribution and functional payload activity is therefore important when optimizing localized delivery.
Direct tumor delivery:Local administration can increase exposure within accessible tumor tissue while reducing dependence on systemic tumor accumulation. Tumor-targeted LNP development can combine local administration with cellular or molecular targeting.
Ocular delivery:Local LNP administration can be designed around specific anterior or posterior ocular barriers and target-cell populations.
Joint and tissue-localized research:Direct administration may be useful where the target tissue is anatomically accessible and widespread systemic exposure is unnecessary.
Topical skin delivery:Intact LNPs face substantial restriction from the stratum corneum, so gels alone should not be assumed to provide deep skin penetration. Physical assistance, penetration-enhancing systems, or skin-barrier-specific formulation strategies may be required.
Tell BOC Sciences your payload, target tissue, intended distribution, dosage format, and current delivery bottleneck. We can compare route feasibility and develop a route-specific formulation and evaluation strategy.
Route selection should occur before extensive formulation optimization because the administration route determines the first set of biological and physical barriers encountered by an LNP. An excellent IV formulation may perform poorly after nebulization, and an effective liquid IM LNP may lose activity after incorporation into a dried microneedle matrix. Route and formulation should therefore be developed as an integrated system.
Systemically accessible targets:IV administration is usually the most direct starting route when broad systemic circulation or hepatic exposure is required.
Lymphoid and vaccine targets:IM, SC, and ID delivery provide access to interstitial and lymphatic transport mechanisms and can be useful when antigen-presenting cells or draining lymph nodes are central to the research objective.
Respiratory targets:Inhaled or intranasal delivery may provide more direct respiratory exposure than systemic administration but requires aerosol- and mucus-compatible formulation design.
GI targets:Oral delivery can provide direct access to intestinal tissue but adds the greatest number of sequential extracellular barriers.
Anatomically accessible tissues:Local administration can reduce reliance on systemic biodistribution when the target can be reached directly.
These options can be considered within broader lipid nanoparticle drug delivery development rather than treating administration route as a downstream decision.
Payload properties can change the preferred route. Large, nuclease-sensitive RNAs require strong protection and cytosolic delivery, making route-induced stresses particularly important. Proteins and peptides may have different loading and release constraints, while small molecules may tolerate dosage forms that are not suitable for RNA. Formulation stability must be tested under conditions that resemble the selected route: serum for IV, interstitial fluids for injection, drying and rehydration for microneedles, GI media for oral delivery, and aerosolization for respiratory delivery. Route-relevant LNP stability evaluation can reveal failure modes that are invisible in standard buffer characterization.
Table 4. Cross-Route Comparison for LNP Delivery Development.
| Route | Primary Delivery Advantage | Major Barrier | Useful Quantitative Benchmark | Route-Specific Evaluation |
| Intravenous | Immediate systemic access | Protein corona and hepatic clearance | pKa ~6.2-6.5 often used for hepatic RNA LNPs | Serum stability and organ/cell distribution |
| IM / SC | Local exposure and lymphatic access | Interstitial trapping and depot retention | 20-100 nm useful lymphatic-drainage window | Injection-site, LN, and APC distribution |
| ID / Microneedle | Direct immune-rich skin access | Drying, matrix compatibility, release | No universal particle range after matrix processing | Pre/post-fabrication LNP comparison |
| Oral | Direct GI access | pH, bile, enzymes, mucus, epithelium | Stomach pH approximately 1-2.5 | Sequential biorelevant-media stability |
| Inhaled | Direct pulmonary deposition | Aerosol stress and airway clearance | Aerosol aerodynamic diameter ~1-5 µm | Post-aerosol LNP integrity and deposition |
| Intranasal | Direct nasal mucosal exposure | Mucociliary clearance and regional deposition | Device- and formulation-dependent | Nasal retention and local uptake |
| Local / Topical | Direct proximity to target tissue | Tissue-specific diffusion barriers | No universal bioavailability value | Spatial distribution and local activity |
Payload type:mRNA, saRNA, siRNA, pDNA, proteins, peptides, and small molecules do not impose identical formulation constraints. Long RNA molecules are particularly sensitive to shear, degradation, and incomplete endosomal escape, while protein and peptide payloads require consideration of structural integrity and release behavior.
Target tissue:Route selection should minimize the number of biological barriers between administration and the intended tissue. Direct local access may be preferable when systemic transport adds unnecessary biodistribution complexity.
Dosing frequency:Repeated administration increases the importance of dosage-form convenience, local tolerability, storage format, and route practicality. These factors should be considered early rather than after formulation selection.
Administration practicality:IV infusion, conventional injection, microneedle delivery, nebulization, nasal administration, oral dosage forms, and direct local injection each require different devices and formulation properties. The simplest route is not necessarily the route with the simplest formulation.
Analytical strategy:Route-specific failure should be separated into exposure, uptake, trafficking, and functional-release problems. Nanoparticle cellular uptake testing determines whether target cells internalize the LNP, whereas LNP endosomal escape evaluation addresses whether internalized cargo reaches the required intracellular compartment.
Table 5. BOC Sciences Support for Route-Specific LNP Development.
| Service | When It Is Useful | Development Scope | Inquiry |
| LNP Process Optimization | When route-specific formulation changes alter particle properties | Mixing, lipid ratio, process parameters, post-processing, and formulation refinement | Inquiry |
| LNP Excipient Screening | When oral, aerosol, microneedle, or local formats add new stresses | Buffers, stabilizers, protectants, route-compatible excipients, and stress screening | Inquiry |
| Ionizable Lipid Optimization | When uptake is measurable but functional RNA delivery remains weak | Ionizable lipid screening, apparent pKa, expression, and route-specific performance | Inquiry |
| Nanoparticle Analysis and Characterization | When processing or administration may alter LNP structure | Size, PDI, zeta potential, morphology, encapsulation, loading, and stability | Inquiry |
| Intracellular Localization Detection | When cellular uptake does not explain functional output | Endosomal, lysosomal, and intracellular trafficking assessment | Inquiry |
Lipid nanoparticle delivery cannot be separated from the route of administration. IV delivery immediately exposes the LNP to plasma proteins and systemic biodistribution mechanisms; IM and SC delivery introduce interstitial transport and lymphatic drainage; intradermal and microneedle systems add skin-layer targeting and solid-state formulation constraints; oral delivery requires sequential protection against gastric, intestinal, mucus, and epithelial barriers; inhaled and intranasal routes require control of aerosol or mucosal transport; and local delivery is dominated by tissue-specific retention and penetration.
Quantitative parameters such as an apparent pKa of approximately 6.2-6.5 for many hepatic RNA-LNP systems, a 20-100 nm lymphatic-drainage window after interstitial administration, approximately 1-3% productive cytosolic escape for many internalized RNA-LNPs, and a 1-5 µm aerodynamic range for many deep-lung aerosol formulations provide useful development references. None should be applied as a universal specification. Their value lies in defining rational starting regions that can then be adjusted according to payload, target tissue, administration route, and measured biological performance.
A robust route-selection strategy therefore combines formulation design with route-relevant stress testing, biodistribution, cellular uptake, intracellular trafficking, and functional payload measurements. BOC Sciences supports this integrated approach from lipid and excipient screening through formulation optimization, characterization, and in vivo distribution evaluation.
